Guardian Pharmacy Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results ATLANTA

Guardian Pharmacy Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

ATLANTA, March 26, 2025 (BUSINESS WIRE) Guardian Pharmacy Services, Inc. ( Guardian ) (NYSE: GRDN), one of the nation s largest

long-term care (LTC) pharmacy services companies, today announced financial results for the fourth quarter and full year ended December 31, 2024.

Fourth Quarter and Full Year Highlights

Months Ended December 31, 2024

Year Ended December 31,

We re proud to report that we ended the year on a strong note, exceeding our expectations for the fourth quarter and year ended December 31,

2024. The outperformance was driven by strong organic growth, acquisitions, and the new benefit of the seasonal trend related to conducting vaccine clinics in certain long-term care facilities we serve. Looking ahead, we enter 2025 well-positioned

for success and we remain committed to continuing to meet the needs of all of the residents we serve, said Fred Burke, President & CEO of Guardian.

Initial 2025 Full Year Guidance

announced, Guardian is providing the following guidance for the full year 2025:

This guidance does not include potential future M&A activity and/or contiguous expansions. Additionally, guidance for Adjusted EBITDA includes a full year

of incremental public company expenses of approximately $4.0 million, compared to just one quarter of related expenses in 2024.

provided a quantitative reconciliation of forecasted Adjusted EBITDA, which is a non-GAAP financial measure to forecasted net income within this release because Guardian is unable, without making unreasonable

efforts, to calculate certain reconciling items with confidence due to the variability and complexity of such items. These items include, but are not limited to, income taxes and share-based compensation. These items, which could materially affect

the computation of forecasted net income, are inherently uncertain and depend on various factors that are not estimable at this time.

Conference Call Information

Guardian will host a conference call to discuss its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025, at 4:30 p.m. ET. The

conference call can also be accessed by dialing +1 (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID 69868. A replay will be available online at

https://investors.guardianpharmacy.com shortly after the call s completion and will remain available for approximately 60 days.

Guardian Pharmacy Services is a leading long-term care pharmacy services company that provides an extensive suite of

technology-enabled services designed to help residents of long-term health care facilities ( LTCFs ) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. As of

December 31, 2024, our 51 pharmacies served approximately 186,000 residents in approximately 7,000 LTCFs across 38 states.

Regarding Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are all statements other than

those of historical fact. Any statements about our expectations, beliefs, plans, predictions, forecasts, objectives, assumptions, or future events or performance are forward-looking. These statements are often, but not always, made through the use

of words such as aims, anticipates, believes, continue, estimates, expects, intends, may, outlook, plans, projects,

seeks, should, will, would, and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements are not guarantees of

future performance and involve risks and uncertainties which are subject to change based on various important factors, many of which are beyond our control. Such risks and uncertainties include: our ability to effectively execute our business

strategies, implement new initiatives and improve efficiency; our ability to effectively market and sell, customer acceptance of, and competition for, our pharmaceutical services in new and existing markets; our relationships with pharmaceutical

wholesalers and key manufacturers, LTCFs and health plan payors; our ability to maintain and expand relationships with LTCF operators on favorable terms; the impact of a national emergency, public health crisis, global pandemic or outbreak of

infectious disease on our employees and business and on our supply chain and the LTCFs we serve; continuing government and private efforts to lower pharmaceutical costs, including by limiting pharmacy reimbursements; changes in, and our ability to

comply with, healthcare and other applicable laws, regulations or interpretations; further consolidation of managed care organizations and other health plan payors and changes in the terms of our agreements with these parties; our ability to retain

members of our senior management team, our local pharmacy management teams and our pharmacy professionals; our exposure to, and the results of, claims, legal proceedings and governmental inquiries; our ability to maintain the security and integrity

of our operating and information technology systems and infrastructure (e.g., against cyber-attacks); product liability, product recall, personal injury or other health and safety issues related to the pharmaceuticals we dispense; the impact of

supply chain and other manufacturing disruptions or trade policies related to the pharmaceuticals we dispense; the sufficiency of our sources of liquidity and financial resources to fund our future operating expenses and capital expenditure

requirements, and our ability to raise additional capital, if needed; the misuse or off-label use, or errors in the dispensing or administration, of the pharmaceuticals we dispense; and volatility of our stock

price. We are subject to additional risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission from time to time, including in the Risk Factors, and Management s Discussion and

Analysis of Financial Condition and Results of Operations sections contained in our most recent Annual Report on Form 10-K, which reports are made publicly available at www.sec.gov and via our website,

investors.guardianpharmacy.com Any forward-looking statements in this press release should be evaluated in light of these important risk factors. This press release reflects management s views as of the date hereof. Except to the extent

required by applicable law, Guardian undertakes no obligation to update or revise any information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise.

Additional Information

This release should be read in

conjunction with the consolidated financial statements and notes thereto included in our most recent Annual Report on Form 10-K and subsequent filings. Copies of our reports are available on our website at no

expense at http:/.investors.guardianpharmacy.com and through the SEC s website at www.sec.gov.

Non-GAAP Financial Measures

To supplement our results prepared in accordance with generally accepted

accounting principles in the United States ( GAAP ), we also present Adjusted EBITDA and Adjusted SG&A, which are non-GAAP financial measures. We define Adjusted EBITDA as net income (loss)

before interest expense, income taxes, depreciation and amortization, as adjusted to exclude the impact of items and amounts that we view as not indicative of our core operating performance, including share-based compensation, acquisition accounting

adjustments, certain legal and regulatory items, and IPO-related costs. We define Adjusted SG&A as GAAP selling, general, and administrative expenses adjusted to exclude the impact of share-based

compensation, expenses relating to certain legal and regulatory items, and IPO-related costs. Adjusted EBITDA and Adjusted SG&A do not have a definition under GAAP, and our definition of Adjusted EBITDA

and Adjusted SG&A may not be the same as, or comparable to, similarly titled measures used by other companies.

We use Adjusted EBITDA and Adjusted SG&A to better understand and evaluate our core operating

performance and trends. We believe that presenting Adjusted EBITDA and Adjusted SG&A provides useful information to investors in understanding and evaluating our operating results, as it permits investors to view our core business performance

using the same metrics that management uses to evaluate our performance.

There are a number of limitations related to the use of Adjusted EBITDA and

Adjusted SG&A rather than the most directly comparable GAAP financial measure, including:

Because of these limitations, Adjusted EBITDA and Adjusted SG&A should not be considered

in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. You should consider Adjusted EBITDA and Adjusted SG&A alongside other financial measures, including net income, GAAP selling, general, and

administrative expense and our other financial results presented in accordance with GAAP. For a reconciliation of Adjusted EBITDA to net income, and Adjusted SG&A to GAAP selling, general, and administrative expense, for the historical periods

presented herein, please see the reconciliation tables below.

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

GUARDIAN PHARMACY SERVICES, INC. AND SUBSIDIARIES

RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED SG&A TO THE MOST DIRECTLY COMPARABLE GAAP FINANCIAL MEASURES